Source link : https://www.newshealth.biz/health-news/survival-win-for-pembrolizumab-in-early-triple-negative-breast-cancer/
PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant improvement in overall survival (OS), according to updated results from a large randomized trial. After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% […]
Author : News Health
Publish date : 2024-09-17 19:49:22
Copyright for syndicated content belongs to the linked Source.